Navigation Links
REGiMMUNE receives $12 million in grants to develop transplant and allergy drugs
Date:12/8/2008

Mountain View, CA and TOKYO December 8, 2008 REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, today announced that it has received two separate grants totaling more than $12 million from the Japan Science and Technology Agency (JST) and from National Institute of Biomedical Innovation (NIBIO). Under terms outlined in the five-year grant from JST, REGiMMUNE will develop its reVax drug for cedar allergy; and the three-year grant from NIBIO will fund the development of its ToleroVax drug (RGI-2001), a new immunosuppressant for Graft-versus-Host Disease (GvHD) associated with stem cell transplantation.

"The substantial funds that REGiMMUNE is receiving from these two prestigious organizations emphasize the importance of alternative financing opportunities that are available to us, despite the current worldwide economic situation," stated Haru Morita, President and Chief Executive Officer of REGiMMUNE. "The financial support from JST and NIBIO also serves to validate the success of the company's research and development capabilities to date, as well as the potential of our ToleroVax and reVax technologies to produce important new pharmaceutical products," Mr. Morita continued.

Earlier this year, REGiMMUNE completed an $8 million Series B financing to advance the company's compound RGI-2001for GvHD. The new grants will be used to complete the preclinical programs for the company's two lead projects, RGI-1001 for cedar allergy and RGI-2001, as well as to provide the initial funding for the clinical programs.


'/>"/>

Contact: Debra Bannister
530-676-8001
REGiMMUNE
Source:Eurekalert

Page: 1

Related biology news :

1. Rutgers Genetics receives $7.8 million for autism research
2. Herr receives Heinz Award for Technology, the Economy and Employment
3. UCI receives $5M from Edwards Lifesciences
4. Yu receives research funding from the Wallace H. Coulter Foundation
5. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
6. UC Riverside biologist receives prestigious MacArthur Fellowship
7. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
8. Penn biochemist receives NIH New Innovators Award
9. NYUs Center for Genomics & Systems Biology receives $4.4 million NSF grant
10. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
11. Alaska graduate program in sustainability receives $3.2 million award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/6/2017)... 6, 2017  Privately-held CalciMedica, Inc., announced that ... volunteers of a novel calcium release-activated calcium (CRAC) ... Acute pancreatitis, sudden painful inflammation ... but can be very serious.  In severe cases it ... extended hospital stays, time in the ICU and ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 Bioptix, ... the "Company"), announced that on January 14, 2017 the ... under which the Company will terminate certain employees associated ... Diagnostics, Inc.  The Company commenced terminations on January 16, ... 30 days.  The Company may pay severance benefits in ...
(Date:1/21/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, today presented data from two clinical ... 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers ... In a Phase Ib/II study of napabucasin ... cancer stemness pathways by targeting STAT3 – colorectal cancer ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... how current market conditions have influenced the most recent ... Regulus Therapeutics Inc. (NASDAQ: RGLS ), Abeona ... Inc. (NASDAQ: TBPH ), and Sage Therapeutics ... new research report by Grand View Research, global Biotech market size ...
(Date:1/20/2017)... January 20, 2017 http://www.Financialbuzz.com ... one of leading causes of death worldwide. There were ... number of cancer related deaths increased gradually over time, ... incidence rate of various cancers continues to drive demand ... report by Global Market Insights, Inc. cancer biological therapy ...
Breaking Biology Technology: